Sachdev Amit, Executive Vice President and Chief Patient & External Affairs Officer at Vertex Pharmaceuticals (VRTX), has demonstrated a pronounced selling bias in recent transactions, with no open-market purchases recorded in the latest filings. Since February 2026, Amit executed nine sales totaling over $30.8 million, including a single-day liquidation of approximately $28.5 million on February 19 alone. The largest transactions that day included sales valued at $9.2 million, $5.5 million, and $4.8 million, supplemented by smaller dispositions ranging from $426,797 to $1.9 million. Earlier that month, Amit disposed of additional shares worth $897,802 on February 25 and $736,396 on February 24, following a pattern of consistent divestment.
Amit’s trading history shows a long-term focus on Vertex, with all 38 recorded transactions involving VRTX shares. While earlier activity included periodic acquisitions—with total buys reaching $8.3 million—the recent direction is decisively weighted toward sales, totaling $48.1 million in gross proceeds. The transactions include a mix of open-market sales (coded "S") and dispositions tied to tax obligations or option exercises (coded "F"). Notably, multiple filings on February 19 coincided with derivative transactions (coded "M") exceeding $8.3 million, likely related to option conversions. The absence of any recent buys, coupled with the scale and frequency of sales, suggests a deliberate reduction in equity exposure to Vertex.
AI-assisted summary